Tenaya Therapeutics Shares Updates Related To Its Ongoing Phase 1b/2 MyPEAK-1 Clinical Trial Of TN-201; TN-201 Has Appropriate Tolerability Profile At 3E13 Vg/kg Dose Without Unexpected Adverse Reactions
Tenaya Therapeutics Shares Updates Related To Its Ongoing Phase 1b/2 MyPEAK-1 Clinical Trial Of TN-201; TN-201 Has Appropriate Tolerability Profile At 3E13 Vg/kg Dose Without Unexpected Adverse Reactions
Tenaya Therapeutics分享了与其正在进行的TN-201 MyPEAk-1临床试验相关的更新；TN-201在3E13 Vg/kg剂量下具有适当的耐受性配置文件，没有发生意外不良反应。
TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy (HCM), a condition caused by insufficient levels of myosin-binding protein C (MyBP-C).
TN-201正在开发，用于潜在治疗由肌球蛋白结合蛋白C（MyBP-C）水平不足造成的MYBPC3相关肥厚型心肌病（HCM）控件。
TN-201 gene replacement therapy is designed to increase protein levels of MyBP-C to slow or even reverse the course of disease by delivering a functional copy of the MYBPC3 gene to heart muscle cells.
TN-201基因替代疗法旨在增加MyBP-C蛋白水平，通过向心肌细胞传递MYBPC3基因的功能拷贝来减缓甚至逆转疾病进程。
Tenaya plans to report initial data from Cohort 1 in December of this year.
Tenaya计划在今年12月报告Cohort 1的初步数据。
资讯热榜
更新时间